Biospecifics Technologies Corporation

Duke University

Advance Biofactures of Curacao

Johns Hopkins University

North Carolina Central University

Advance Biofactures of Curacao, N.v.

Advance Biofactures Corporation

Endo Biologics, Inc.

Auxilium International Holdings, Inc.

Thomas L Wegman

Phyllis Carolyn Leppert

Bo Yu

Darlene K Taylor

James H Segars

Phillip J Bassett

Jean-Marie Soma

Gregory L Sabatino

Hazel A Tharia

Antony G Hitchcock

Benjamin J Del Tito

Jr Benjamin J Del Tito

Disclosed herein are compositions and methods for treating uterine fibroids in vivo, and methods of reducing symptoms associated with uterine fibroids, including pain, bleeding and infertility. The disclosed compositions comprise collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids.

Treatment of uterine fibroids using purified collagenase

Compositions and methods for treating uterine fibroids are described, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.

Treatment method and product for uterine fibroids using purified collagenase

The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.

It is an object of the present disclosure to provide a formulation for injectable collagenase which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pregelation, which would interfere with the ability to deliver the required dose for treatment.

Thermosensitive hydrogel collagenase formulations

The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from. The method utilizes an improved medium for the cultivation ofwhich includes a non-meat-derived (i.e., non-mammalian) peptone or vegetable peptone. The method includes one or more of: (1) reducing glucose content in the meat-free or vegetable-derived media; and (2) increasing the salt concentration in the meat-free or vegetable-derived media. Also provided is a drug product which includes collagenase I and collagenase II at an optimized fixed mass ratio, and which has a purity of greater than at least 95%.

Compositions and methods for producing clostridial collagenases

The cords of Dupuytren's disease are injected with collagenase, the hand is immediately immobilized and maintained immobile for several hours. The cord becomes relaxed or ruptured, relieving the hand contracture of the disease.

Amelioration of Dupuytren's disease

Amelioration of dupuytren's disease

A method of treating an individual suffering from Peyronie's disease. Collagenase is injected into a fibrous Peyronie's plaque in the penis of the individual suffering from the disease. The penis immediately after injection, is immobilized and maintained immobile for several hours. The collagenase is in a pharmaceutically acceptable carrier in a concentration of about 20,000 to about 40,000 ABC units per ml., and the amount and concentration of the collagenase is effective to soften and/or rupture the plaque whereby the erectile deviation caused by the plaque is ameliorated

Amelioration of peyronie's disease

Dupuytren's disease is treated by applying collagenase to the affected palmar fascia.

Growing community of inventors

N. Merrick, NY, United States of America

Thomas L Wegman